Surface antigens expressed by Pno lymphocytes and patient PBLs
| Surface antigen . | Antibody . | Reactivity* . | |
|---|---|---|---|
| Pno . | Patient PBLs . | ||
| CD3 | IP30 | ++ | ++ |
| TCR-Vβ22 | IMMU 546 | ++ | ++ |
| CD4 | IP34 C | ++ | ++ |
| CD8α | IP48 | ++ | ++ |
| CD8α/β | 2 ST8-5 H7 | − | − |
| CD2 | CD2X11 | ++ | ++ |
| CD2R | GT2 | + | + |
| MHC class I | W6/32 | ++ | ++ |
| MHC class II | L242 | − | − |
| CD25 | BC 96 | − | − |
| CD122 | TU 27 | + | + |
| CD132 | 3B5 | ++ | ++ |
| CD28 | CD28.2 | ++ | ++ |
| CD95 | APO-1 | ++ | ++ |
| CD158a | EB6 | − | − |
| CD158b | GL 183 | − | − |
| CD94 | HP-3B1 | − | − |
| CD1a | L544 | − | − |
| CD1b | O249 | − | − |
| CD1c | L161 | − | − |
| HLA-G | BFL1 | − | − |
| CD30 | By 88.9 | − | − |
| Surface antigen . | Antibody . | Reactivity* . | |
|---|---|---|---|
| Pno . | Patient PBLs . | ||
| CD3 | IP30 | ++ | ++ |
| TCR-Vβ22 | IMMU 546 | ++ | ++ |
| CD4 | IP34 C | ++ | ++ |
| CD8α | IP48 | ++ | ++ |
| CD8α/β | 2 ST8-5 H7 | − | − |
| CD2 | CD2X11 | ++ | ++ |
| CD2R | GT2 | + | + |
| MHC class I | W6/32 | ++ | ++ |
| MHC class II | L242 | − | − |
| CD25 | BC 96 | − | − |
| CD122 | TU 27 | + | + |
| CD132 | 3B5 | ++ | ++ |
| CD28 | CD28.2 | ++ | ++ |
| CD95 | APO-1 | ++ | ++ |
| CD158a | EB6 | − | − |
| CD158b | GL 183 | − | − |
| CD94 | HP-3B1 | − | − |
| CD1a | L544 | − | − |
| CD1b | O249 | − | − |
| CD1c | L161 | − | − |
| HLA-G | BFL1 | − | − |
| CD30 | By 88.9 | − | − |
The reactivity is the relative intensity of staining compared with isotype controls; ++ indicates strong staining; +, moderate; and −, negative.